tividenofusp alfa
Phase 2/3Recruiting 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis II
Conditions
Mucopolysaccharidosis II
Trial Timeline
Sep 20, 2023 → Jun 1, 2027
NCT ID
NCT06075537About tividenofusp alfa
tividenofusp alfa is a phase 2/3 stage product being developed by Denali Therapeutics for Mucopolysaccharidosis II. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06075537. Target conditions include Mucopolysaccharidosis II.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06075537 | Phase 2/3 | Recruiting |
| NCT04251026 | Phase 1/2 | Active |
Competing Products
20 competing products in Mucopolysaccharidosis II